McKesson Corp. stock slides 1.48 percent and underperforms competitors

6 articles · Updated · MarketWatch · Apr 29

Shares closed at $822.63 on Wednesday, snapping a two-day winning streak and trading 17.65% below the March 3rd 52-week high.
McKesson's decline came amid a broadly weak market, with the S&P 500 and Dow Jones also falling, while competitors like Amazon, UnitedHealth, and CVS Health posted gains.
Trading volume for McKesson reached 789,662, surpassing its 50-day average, highlighting increased investor activity during a generally dismal session for the stock market.

McKesson's stock fell while its rivals rose; is this a company-specific problem?

Is Amazon's entry into drug wholesale a real threat to McKesson's dominance?

How will McKesson's new CFO navigate the company's margin pressures and strategic shifts?

As blockbuster GLP-1 drugs squeeze profits, can McKesson innovate beyond simple distribution?

Will McKesson's surgical unit IPO unlock new value or expose its core business?

With direct-to-consumer pharma rising, is the traditional 'middleman' model becoming obsolete?